Net sales rose MSEK 42.5 compared with the first quarter of 2014
FIRST QUARTER 2015
• NET SALES amounted to MSEK 68.9 (26.4).
• OPERATING PROFIT totalled MSEK 27.3 (6.1).
• PROFIT AFTER TAX amounted to MSEK 22.4 (5.0).
• PROFIT AFTER TAX PER SHARE was SEK 2.45 (0.55).
• TOTAL CASH FLOW amounted to MSEK 18.5 (3.6).
SIGNIFICANT EVENTS DURING THE FIRST QUARTER:
• Probi secured a record order valued at MSEK 17 from US company NBTY, which was delivered in the first quarter.
• Probi entered into long-term research collaboration with Wageningen University in the Netherlands.
• The partnership agreement with DKSH was expanded to include launches of Probi Digestis® in Hong Kong and Macau.
• Probi signed a distribution agreement with Jamieson for the launch of Probi Digestis in Canada.
CEO’S COMMENTS:
“2015 started on a high note for Probi. Our net sales of MSEK 68.9 (26.4) are more than double the figure for the first quarter of 2014. This strong growth is very much attributable to stock accumulations by our US partners Pharmavite and NBTY prior to future launches later this year. At present, we do not expect net sales in the forthcoming quarters to reach the same level as in the first quarter. However, in line with previous guidance, we are still expecting strong year-on-year growth for 2015. In the second quarter, the organisation will be strengthened with seven new employees to create opportunities for capitalising on the sharply increased demand for our products. We are also very pleased to have entered into long-term research collaboration with Professor Michiel Kleerebezem, Wageningen University, the Netherlands, a leader in research into the mechanisms of action of probiotic bacteria. We hope that this collaboration will eventually result in new effective probiotic products,” says Peter Nählstedt, CEO for Probi.
INVITATION TO TELECONFERENCE (SWEDISH):
Time: Thursday, 23 April 2015 at 10.00 a.m. Phone number: +46 (0)8 566 426 61 Participants from Probi: Peter Nählstedt, CEO and Niklas Brandt, CFO. The presentation is available at www.probi.se and www.financialhearings.com
FOR FURTHER INFORMATION, PLEASE CONTACT:
Peter Nählstedt, CEO Probi, tel: +46 (0)46-286 89 23 or +46 (0)723-86 99 83, e-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO, Probi, tel: +46 (0)46-286 89 26 or +46 (0)706-62 98 83, e-mail: niklas.brandt@probi.se
This information is such that Probi AB is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 23 April 2015 at 8:45 a.m.
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2014, Probi had sales of MSEK 135. The Probi share is listed on NASDAQ OMX Stockholm, Small Cap. Probi has about 3,000 shareholders. Read more at www.probi.se.
Tags: